Effective thrombolysis by a recombinant Escherichia coli produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis

Fibrinolysis

Volumn 10, Issue 2, 1996, Pages 87-92

  Martin, U ^a   Kohnert, U ^a   Hellerbrand, K ^a   Stern, A ^a   Popp, F ^a   Doerge, L ^a   Stegmeler, K ^a   Muller Beckmann B ^a   Fischer, S ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RETEPLASE; STREPTOKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

EID: 0029938977     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80083-X     Document Type: Article

References (19)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-682.
2. Lincoff A M, Topol E J. Illusion of reperfusion - does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 87: 1792-1805.
3. Smalling R W, Bode S, Kalbfleisch J et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-2732.
4. Bode C, Smalling R W, Kalbfleisch J et al. Randomized comparison of double bolus reteplase (rPA) and front-loaded alteplase in patients with acute myocardial infarction (RAPID II). Eur Heart J 1995; 11 (abstr. suppl.): abstr. 131.
5. Mellot M J, Sabilito I I, Holahan M A et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992; 12: 212-221.
6. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning W-D. Coronary thrombolysis with desmodus salivary plasminogen activator in dogs - fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-426.
7. Keyt B A, Paoni N F, Refino C J et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674.
8. Verheijen J H, Caspers M P M, Chang G T G, de Munk G A W, Pouwels P H, Enger-Valk B E. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-3530.
9. Dodd I, Fears R, Robinson J H. Isolation and preliminary characterization of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemost 1986; 55: 94-97.
10. Rijken D C, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-3102.
11. Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant E. coli-derived protease-domain of tissue type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10: 00-00.
12. Collen D, Stassen J M, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest 1983; 71: 368-376.
13. Martin U, Fischer S, Kohnert U et al. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991; 65: 560-564.
14. Kohnert U, Rudolph R, Verheijen J H et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5:93-100.
15. Martin U, von Möllendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostas 1991; 66: 569-574.
16. Conover W J, Iman R L. Rank transformation as a bridge between parametric and nonparametric statistics. American Statistician 1981; 35: 124-133.
17. Hotchkiss A, Refino C J, Leonard C K et al. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 60: 255-261.
18. Kohnert U, Horsch B, Fischer S. A variant of tissue type plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 1993; 7: 365-372.
19. Montoney M, Gardell S J, Marder V J. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-1544.